Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. On 31 December 2023, the US$4.0b market-cap company posted a loss of US$552m for its most recent financial year. Many investors are wondering about the rate at which Alvotech will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. Check out our latest analysis for Alvotech Alvotech is bordering on breakeven, according to the 5 American Biotechs analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$125m in 2025. Therefore, the company is expected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 89% is expected, which is rather opti
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar [Yahoo! Finance]Yahoo! Finance
- Alvotech GAAP EPS of -$0.89, revenue of $12.43M; raises FY24 topline revenue guidance [Seeking Alpha]Seeking Alpha
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateGlobeNewswire
- Alvotech and Dr. Reddy's collaborate for commercialization of denosumab [Seeking Alpha]Seeking Alpha
ALVO
Earnings
- 5/21/24 - Miss
ALVO
Sec Filings
- 5/22/24 - Form 6-K
- 5/21/24 - Form 6-K
- 5/21/24 - Form 6-K
- ALVO's page on the SEC website